PTC-209 (PTC209) is a specific BMI-1 inhibitor with IC50 of 0.5 uM, irreversibly impairs colorectal cancer-initiating cell (CIC) growth.
PTC-209 causes cell cycle arrest at the G1/S checkpoint in biliary tract cancer (BTC) cells, decreases BMI1 and increases p16 protein expression in canine OSA cell lines.
PTC-209 reduces tumor growth in CIC xenograft assays and abrogates colorectal cancer cell self-renewal in vivo, reducing their tumorigenic potential.
